2017
DOI: 10.1016/j.fct.2016.11.015
|View full text |Cite
|
Sign up to set email alerts
|

Low dose assessment of the carcinogenicity of furan in male F344/N Nctr rats in a 2-year gavage study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
40
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 48 publications
(40 citation statements)
references
References 59 publications
0
40
0
Order By: Relevance
“…Other significant changes observed were biliary tract hyperplasia, cytoplasmic vacuolisation of oval cells and regenerative hypertrophy (Table ). Interim analyses at 36 and 60 weeks showed similar responses with the significance at lower doses increasing with the time (NCTR, ; Von Tungeln et al., ).…”
Section: Assessmentmentioning
confidence: 87%
See 1 more Smart Citation
“…Other significant changes observed were biliary tract hyperplasia, cytoplasmic vacuolisation of oval cells and regenerative hypertrophy (Table ). Interim analyses at 36 and 60 weeks showed similar responses with the significance at lower doses increasing with the time (NCTR, ; Von Tungeln et al., ).…”
Section: Assessmentmentioning
confidence: 87%
“…Samples (23 from 2 mg/kg bw and 6 from 8 mg/kg bw) from the NTP study (1993) were re‐examined following the guidelines described by Thoolen et al. () and it is now clear that cholangiocarcinomas were only observed at the highest dose (NCTR, ; Von Tungeln et al., ) while cholangiofibrosis was observed at the lower doses.…”
Section: Assessmentmentioning
confidence: 99%
“…The BMD is used to derive a “Point of Departure” (PoD), a dose used to calculate the MoE with estimated human dietary exposure. Several groups, including food safety authorities, have included BMD modeling in their reports (Carthew, DiNovi, & Setzer, ; EFSA, ; JECFA, ; Von Tungeln et al., ). JECFA () selected the study of Moser et al.…”
Section: Aspects Important For Risk Assessmentmentioning
confidence: 99%
“…Using the combination of this and the data set from the previous NTP study (NTP, ), EFSA determined a BMDL 10 of 1.31 mg/kg bw/day for the same endpoint, following the EFSA guidelines for BMD modeling (EFSA, ). BMD modeling was recently also applied to the non‐neoplastic endpoint of cholangiofibrosis in rats (EFSA, ; Von Tungeln et al., ). Again, slightly different BMDL 10 levels were obtained by EFSA, following the EFSA guidelines (BMDL 10 of 0.064 mg/kg bw/day), compared to the modeling following the EPA suite for BMD modeling (BMDL 10 of 0.11 to 0.12 mg/kg bw/day), based on the same rodent data set (Von Tungeln et al., ).…”
Section: Aspects Important For Risk Assessmentmentioning
confidence: 99%
See 1 more Smart Citation